Home GPCR & G Protein Angiotensin Receptor

Angiotensin Receptor Antagonists

Cat.No. Product Name Information Product Use Citations Product Validations
S5067 Losartan Losartan(DuP-753) is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.
Sci Rep, 2025, 15(1):12955
Sci Adv, 2025, 11(23):eadu2695
Eur J Med Res, 2024, 29(1):109
S1578 Candesartan Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
J Immunother Cancer, 2024, 12(11)e009805
Front Pharmacol, 2022, 13:828643
Hypertension, 2021, 77(5):1723-1736
Verified customer review of Candesartan
S1738 Telmisartan Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Sci Rep, 2025, 15(1):22112
Scientific Reports, 2025, 22112
J Immunother Cancer, 2024, 12(11)e009805
Verified customer review of Telmisartan
S7098 PD123319 PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Anticancer Research, 2024, 5263-5270
Cell Res, 2021, 10.1038/s41422-020-00464-8
Int J Biochem Cell Biol, 2020, 121:105703
Verified customer review of PD123319
S1359 Losartan Potassium (DuP 753) Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
J Immunother Cancer, 2024, 12(11)e009805
Commun Biol, 2024, 7(1):1581
Int J Mol Sci, 2023, 24(4)3564
Verified customer review of Losartan Potassium (DuP 753)
S1507 Irbesartan Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
J Immunother Cancer, 2024, 12(11)e009805
Xenobiotica, 2020, 10.1080/00498254.2020.1745318
Front Physiol, 2019, 10:681
Verified customer review of Irbesartan
S1894 Valsartan Valsartan is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
World J Gastroenterol, 2025, 31(33):109562
J Immunother Cancer, 2024, 12(11)e009805
Arch Toxicol, 2022, 96(4):1065-1074
Verified customer review of Valsartan
S2037 Candesartan Cilexetil Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.
bioRxiv, 2025, 2025.05.14.654016
J Immunother Cancer, 2024, 12(11)e009805
Int J Mol Sci, 2022, 23(20)12326
Verified customer review of Candesartan Cilexetil
S3046 Azilsartan Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.
J Immunother Cancer, 2024, 12(11)e009805
Frontiers in Pharmacology, 2021, 774709
Front Pharmacol, 2021, 12:774709
Verified customer review of Azilsartan
S4102 Eprosartan Mesylate Eprosartan(SKF-108566J) is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
J Immunother Cancer, 2024, 12(11)e009805
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
bioRxiv, 2020, 10.1101/2020.10.13.337774
Verified customer review of Eprosartan Mesylate
S1604 Olmesartan Medoxomil Olmesartan Medoxomil (CS-866,RNH-6270) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.
J Immunother Cancer, 2024, 12(11)e009805
Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505
Sci Rep, 2015, 5:8116
Verified customer review of Olmesartan Medoxomil
S3057 Azilsartan Medoxomil Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.
J Immunother Cancer, 2024, 12(11)e009805
Acta Pharm Sin B, 2023, 13(2):662-677
Sci Rep, 2015, 5:8116
Verified customer review of Azilsartan Medoxomil
S5581 Olmesartan Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.
J Immunother Cancer, 2024, 12(11)e009805
Frontiers of Medicine, 2021, 1-11
bioRxiv, 2020, 10.1101/2020.10.13.337774
S8695 ML221 ML221 is a potent apelin receptor (APJ) functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. The IC50 values of ML221 are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively.
Nat Commun, 2022, 13(1):4229
J Mol Cell Cardiol, 2021, S0022-2828(21)00246-7
Research Square, 2021, 10.21203/rs.3.rs-916525/v1
E0039 A-779

A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. This compound shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.
Int J Biol Sci, 2023, 19(8):2613-2629
Elife, 2022, 11e72266
S4975 Fimasartan Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Drug Metab Dispos, 2020, 48(12):1264-1270
S0326 Olodanrigan (EMA401) Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Its analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
S5980 Losartan Carboxylic Acid (EXP-3174) Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. This compound inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.
E4951 Eprosartan Eprosartan (Teveten, SK-108566) is a selective, competitive, nonpeptide and orally active antagonist of angiotensin II receptor. This compound binds angiotensin II receptors with IC50 values of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively.
S6665 Sparsentan (PS-433540, RE-021) Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Front Pharmacol, 2022, 13:964370
Biomedicines, 2021, 86
Biomedicines, 2021, 10(1)86